Magnetic resonance spectroscopy imaging-directed transrectal ultrasound biopsy increases prostate cancer detection in men with prostate-specific antigen between 4-10ng/mL and normal digital rectal examination

International Journal of Urology

Volumn 21, Issue 3, 2014, Pages 257-262

  Javali, Tarun Dilip ^a   Dwivedi, Durgesh Kumar ^a   Kumar, Rajeev ^a   Jagannathan, Naranamangalam Raghunathan ^a   Thulkar, Sanjay ^a   Dinda, Amit Kumar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Magnetic resonance spectroscopic imaging; Prostate cancer; Transrectal ultrasound guided biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CHRONIC PROSTATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SIZE; RETROSPECTIVE STUDY; SENSITIVITY AND SENSIBILITY; TRANSRECTAL ULTRASONOGRAPHY;

MAGNETIC RESONANCE SPECTROSCOPIC IMAGING; PROSTATE CANCER; TRANSRECTAL ULTRASOUND-GUIDED BIOPSY;

DIGITAL RECTAL EXAMINATION; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84896726054     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12258     Document Type: Article

References (37)

1. American Urological Association Education and Research, Inc. Prostate-specific antigen (PSA) best practice statement: 2009 update. [Cited 14 Aug 2013.] Available from URL: http://www.auanet.org/education/guidelines/prostate-specific-antigen.cfm
2. Wilson SS, Crawford ED. Screening for prostate cancer: current recommendations. Urol. Clin. North Am. 2004; 31: 219-226.
3. 1H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml. NMR Biomed. 2007; 20: 11-20.
4. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol. 1989; 142: 71-75.
5. Jradi MA, Dridi M, Teyeb M etal. The 20 core prostate biopsy as an initial strategy: impact on the detection of prostate cancer. Can. Urol. Assoc. J. 2010; 4: 100-104.
6. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterization of prostate cancer: a critical analysis of the literature. Eur. Urol. 2007; 52: 1309-1322.
7. Wefer AE, Hricak H, Vigneron DB etal. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J. Urol. 2000; 164: 400-404.
8. Swanson MG, Vigneron DB, Tabatabai L etal. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D- MRSI-targeted postsurgical prostate tissues. Magn. Reson. Med. 2003; 50: 944-954.
9. Jagannathan NR, Kumar V, Kumar R, Thulkar S. Role of magnetic resonance methods in the evaluation of prostate cancer: an Indian perspective. MAGMA 2008; 21: 393-407. Erratum 2008; 21: 409.
10. Qayyum A, Coakley FV, Lu Y etal. Organ confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am. J. Roentgenol. 2004; 183: 1079-1083.
11. Mescher M, Tannus A, Johnson OM, Garwood M. Solvent suppression using selective echo dephasing. J. Magn. Reson. A 1996; 123: 226-229.
12. 1H MR spectroscopic imaging to segregate patients who are likely to show malignancy of the peripheral zone of the prostate on biopsy. J. Magn. Reson. Imaging 2009; 30: 842-848.
13. Kumar R, Nayyar R, Kumar V etal. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study. Urology 2008; 72: 859-863.
14. Agarwal MS, Sinha S, Juyal S, Gupta AK. Measurement of serum PSA in benign and malignant enlargements of prostate in Indian population: relevance of PSAD in Intermediate range PSA. Ind. J. Urol. 2004; 20: 138-143.
15. Ganpule AP, Desai MR, Manohar T, Bapat S. Age -specific prostate specific antigen and prostate specific antigen density values in a community based Indian population. Ind. J. Urol. 2007; 23: 122-125.
16. Scher HI, Isaacs JT, Zelefsky MJ etal. Prostate cancer. In: Abeloff MD, Armitage JO, Lichter AS etal. (eds). Clinical Oncology, 2nd edn. Churchill Livingstone, New York, 2000; 1823-1884.
17. Dwivedi DK, Kumar V, Javali T etal. A positive magnetic resonance spectroscopic imaging with negative initial biopsy may predict future detection of prostate cancer. Ind. J. Urol. 2012; 28: 243-245.
18. 3) spatial resolution. Radiology 1996; 19: 795-805.
19. Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J. Urol. 2000; 163: 163-166; discussion 166-7.
20. Terris MK, Wallen EM, Stamey TA. Comparison of mid- lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. Urol. Int. 1997; 59: 239-242.
21. Babaian RJ, Toi A, Kamoi K etal. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J. Urol. 2000; 163: 152-157.
22. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J. Urol. 2001; 166: 86-91; discussion 91-2.
23. 1H MRSI based TRUS guided biopsies in men with suspected prostate cancer. Proc. Intl. Soc. Mag. Reson. Med. 2006; 14: 1790.
24. Lian J, Xing L, Hunjan S etal. Mapping of the prostate in endorectal coil-based MRI/MRSI and CT: a deformable registration and validation study. Med. Phys. 2004; 31: 3087-3094.
25. Singh AK, Kruecker J, Xu S etal. Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int. 2008; 101: 841-845.
26. Haffner J, Lemaitre L, Puech P etal. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging - targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011; 108: E171-178.
27. Lemaitre L, Puech P, Poncelet E etal. Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur. Radiol. 2009; 19: 470-480.
28. Bouye S, Potiron E, Puech P, Leroy X, Lemaitre L, Villers A. Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology. Prostate 2009; 69: 105-113.
29. Shimizu T, Nishie A, Ro T etal. Prostate cancer detection: the value of performing an MRI before a biopsy. Acta Radiol. 2009; 9: 1080-1088.
30. Testa C, Schiavina R, Lodi R etal. Accuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy. NMR Biomed. 2010; 23: 1017-1026.
31. Kobus T, Hambrock T, Hulsbergen-van de Kaa CA etal. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an Endorectal coil. Eur. Urol. 2011; 60: 1074-1080.
32. Fradet V, Kurhanewicz J, Cowan JE etal. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 2010; 256: 176-183.
33. Ahmed HU, Moore C, Emberton M. Minimally invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg. Oncol. 2009; 18: 219-232.
34. Dall'Era MA, Cooperberg MR, Chan JM etal. Active surveillance for early- stage prostate cancer: review of the current literature. Cancer 2008; 112: 650-659.
35. Vargas HA, Akin O, Shukla-Dave A etal. Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology 2012; 265: 478-487.
36. Ahmed HU, Kirkham A, Arya M etal. Is it time to consider a role for MRI before prostate biopsy? Nat. Rev. Clin. Oncol. 2009; 6: 197-206.
37. Kumar V, Jagannathan NR, Thulkar S, Kumar R. Prebiopsy magnetic resonance spectroscopy and imaging in the diagnosis of prostate cancer. Int. J. Urol. 2012; 19: 602-613.